BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC:SNTI) today announced that Leslie J. Browne, Ph.D., the Company’s President and Chief Executive Officer, is being treated for a medical condition that may limit his time to travel and attend public events. However, Dr. Browne will continue with his day-to-day duties and responsibilities as President and CEO of the Company. The Senesco Board has agreed to assist Dr. Browne with certain activities, including Harlan Waksal, M.D., Chairman of Senesco, who will take the lead on certain public activities like investor relations. The Board will continue to monitor Dr. Browne’s responsibilities as his treatment progresses.
Dr. Waksal stated, “Les has the full support of the Board as he manages the Company during this period of time, and we wish him a healthy recovery.”
In order to provide Dr. Browne and his family the privacy that they deserve, we will not be commenting further regarding Dr. Browne’s medical condition.
About Senesco Technologies, Inc.
Senesco, a leader in eIF5A technology, is sponsoring a clinical study to evaluate its lead therapeutic candidate SNS01-T in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma. SNS01-T targets B-cell cancers and selectively induces apoptosis by modulating eukaryotic translation initiation factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and biofuels development, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ commercialized products. Senesco routinely posts important information on the Company’s web site, www.senesco.com, and Senesco encourages investors to check the web site periodically for important updates.
Forward-Looking Statements
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company’s ability to continue as a going concern; the Company’s ability to recruit patients for its clinical trial; the ability of the Company to consummate additional financings; the Company’s ability to attract and retain qualified scientific and business personnel; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance, the quotation of the Company’s common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"), as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC and the Company’s periodic disclosures on the Company’s web site, www.senesco.com. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.